|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, these results suggest that CHI3L1 plays an important role in the regulation of malignant transformation and local invasiveness in gliomas.
|
20506295 |
2011 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A complex of nuclear factor I-X3 and STAT3 regulates astrocyte and glioma migration through the secreted glycoprotein YKL-40.
|
21953450 |
2011 |
|
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Although YKL-40 expression is up-regulated in glioblastoma multiforme, its regulation and functions in nontransformed cells of the central nervous system are widely unexplored.
|
21953450 |
2011 |
|
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
YKL-40 up-regulated VEGF expression in glioblastoma cell line U87, and both YKL-40 and VEGF synergistically promote endothelial cell angiogenesis.
|
21385870 |
2011 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The objective of this study was to evaluate, in a series of 43 pediatric high-grade gliomas (21 anaplastic astrocytoma WHO grade III and 22 glioblastoma WHO grade IV), the prognostic value of histological grading and expression of p53 and YKL-40.
|
20174854 |
2010 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The YKL-40 coding chitinase 3-like 1 gene is 1 of the most overexpressed genes in human glioblastomas.
|
20499402 |
2010 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
YKL-40 expression was higher in GBMs than AOs (P < 0.0001) and among GBMs, YKL-40 expression was lower in tumors with either EGFR amplification (P = 0.005) or elevated EGFR expression (P = 0.001).
|
20224722 |
2010 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Resveratrol represses YKL-40 expression in human glioma U87 cells.
|
21029458 |
2010 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Relative YKL-40 expression was compared with glioma class, key molecular alterations, and immunohistochemical markers via a series of Spearman rank correlations.
|
20224722 |
2010 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
YKL-40 may be an attractive target for glioma therapy.
|
20499402 |
2010 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that in pediatric high-grade gliomas: (i) histological grading does not have strong prognostic significance, (ii) YKL-40 overexpression is less frequent than adult high-grade gliomas and does not correlate with a more aggressive behavior, (iii) TP53 mutations but not p53 expression may correlate with a more aggressive behavior, and (iv) IDH1 mutations are absent.
|
20174854 |
2010 |
|
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The objective of this study was to evaluate, in a series of 43 pediatric high-grade gliomas (21 anaplastic astrocytoma WHO grade III and 22 glioblastoma WHO grade IV), the prognostic value of histological grading and expression of p53 and YKL-40.
|
20174854 |
2010 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
CTD_human |
Resveratrol represses YKL-40 expression in human glioma U87 cells.
|
21029458 |
2010 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
High YKL-40 protein expression assessed by immunohistochemistry is found in breast carcinomas associated with short disease-free survival and in glioblastomas with increased resistance to radiotherapy and decreased overall survival.
|
19347297 |
2009 |
|
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Taken together our data suggest that the variant allele (-131C-->G) of CHI3L1 promoter has no significant impact on survival and is not a prognostic factor for glioblastoma.
|
19255724 |
2009 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Serum YKL-40 and bone marrow angiogenesis in multiple myeloma.
|
19089918 |
2009 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Intracranial injection of purified CD133+, not CD133- GBM daughter cells, can lead to the development of YKL-40+ infiltrating tumors that display hypervascularity and pseudopalisading necrosis-like features in mouse brain.
|
19468690 |
2009 |
|
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Taken together our data suggest that the variant allele (-131C-->G) of CHI3L1 promoter has no significant impact on survival and is not a prognostic factor for glioblastoma.
|
19255724 |
2009 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glioblastoma.
|
18092325 |
2008 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CHI3L2, IL1B, PI3/elafin and CHI3L1, which encodes for YKL-40, a putative prognosticator for various diseases, including cancer, were strongly up-regulated in avascular glioma.
|
18092325 |
2008 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Even though TNF-alpha causes recruitment of p65 and p50 subunits of NF-kappaB to the YKL-40 promoter in all cell types, recruitment of histone deacetylases (HDAC)-1 and -2, and a consequent deacetylation of histone H3 at the YKL-40 promoter occurs only in glioma cells.
|
18708058 |
2008 |
|
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Selective repression of YKL-40 by NF-kappaB in glioma cell lines involves recruitment of histone deacetylase-1 and -2.
|
18708058 |
2008 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Anaplastic glioma patients with no radiographic evidence of disease (n = 32 patients, 107 samples) also had a significantly lower level of YKL-40 compared with those patients with active tumor (n = 48 patients, 199 samples; P = 0.04).
|
17020973 |
2006 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
YKL-40 expression is strongly elevated in serum and biopsy material from glioblastomas patients.
|
15771622 |
2005 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
YKL-40 expression was also compared with genetically defined subsets of glioblastoma by assessing epidermal growth factor receptor amplification and loss at chromosome 10q, two of the common recurring aberrations in these tumors, using fluorescent in situ hybridization.
|
15867231 |
2005 |